|
|
|
| Effect of Triptolide on Inflammatory Response of Acute Gouty Arthritis Rats by Adjusting TXNIP/NLRP3 Pathway |
| ZHAO Xiaoyan, LI Zhipeng, XU Kang |
| The Affiliated Hospital of Shijiazhuang Medical College, Hebei Shijiazhuang 50000, China |
|
|
|
|
Abstract Objective: To investigate the effect of triptolide (TPL) on inflammatory response of acute gouty arthritis (AGA) rats by adjusting TXNIP/NLRP3 pathway. Methods: SD rats were assigned into sham surgery group (Sham), AGA group, AGA+TPL group, AGA+TPL+Ad-NC group, and AGA+TPL+Ad-TXNIP group, each with 12 rats. The degree of ankle joint swelling was measured before modeling and at 4 hours, 8 hours, 24 hours and 48 hours of modeling. Reactive oxygen species (ROS) and superoxide dismutase (SOD) activity detection kits were used to measure ROS and SOD activities. Enzyme-linked immunosorbent assay (ELISA) was used to measure interleukin (IL)-1β and IL-18 in ankle joint tissue. Hematoxylin-eosin (HE) staining was used to observe the ankle joint tissues. Immunohistochemical staining was used to observe TXNIP in ankle joint tissues. Western blot experiments were used to test TXNIP/NLRP3 pathway related proteins. Results: For the Sham group, the AGA group showed clearly increased swelling degree of ankle joint at each time point, ROS, IL-1β, IL-18, TXNIP, NLRP3, and Caspase 1 (P<0.05), and clearly decreased SOD activity (P<0.05) in rats, the synovial tissue was clearly thickened, inflammatory cells were increased, chondrocytes were noticeably swollen, and joint swelling occurred. For the AGA group, the AGA+TPL group showed clearly decreased swelling degree of ankle joint at 8, 24, and 48 hours after modeling, ROS, IL-1β, IL-18, TXNIP, NLRP3, and Caspase 1 (P<0.05), and clearly increased SOD activity (P<0.05) in rats, the thickness of inflammatory cells and synovial tissue decreased, and inflammation and edema were alleviated. For the AGA+TPS+Ad-NC group, the AGA+TPS+Ad-TXNIP group showed clearly increased swelling degree of ankle joint at 8, 24, and 48 hours after modeling, ROS, IL-1β, IL-18, TXNIP, NLRP3, and Caspase 1 (P<0.05), and clearly decreased SOD activity (P<0.05) in rats, the inflammatory cells and synovial tissue thickness increased, but severe inflammation and edema still occurred in the joints. Conclusion: TPL may alleviate ankle joint injury in AGA rats by adjusting key proteins in TXNIP/NLRP3 pathway, reducing inflammatory response and oxidative stress.
|
|
|
|
|
|
[1] Dalbeth N,Choi HK,Joosten LAB,et al.Gout[J].Nat Rev Dis Primers,2019,5(1):69.
[2] El-Tantawy WH.Natural products for the management of hyperuricaemia and gout:a review[J].Arch Physiol Biochem,2021,127(1):61-72.
[3] Cheng Y,Huang X,Tang Y,et al.Effects of evodiamine on ROS/TXNIP/NLRP3 pathway against gouty arthritis[J].Naunyn Schmiedebergs Arch Pharmacol,2024,397(2):1015-1023.
[4] Richette P,Doherty M,Pascual E,et al.2018 updated European League against rheumatism evidence-based recommendations for the diagnosis of gout[J].Ann Rheum Dis,2020,79(1):31-38.
[5] Zhang S,Li D,Fan M,et al.Mechanism of reactive oxygen species-guided immune responses in gouty arthritis and potential therapeutic targets[J].Biomolecules,2024,14(8):978.
[6] Yanai H,Adachi H,Hakoshima M,et al.Molecular biological and clinical understanding of the pathophysiology and treatments of hperuricemia and its association with metabolic syndrome,cardiovascular diseases and chronic kidney disease[J].Int Mol Sci,2021,22(17):9221.
[7] Gao J,Zhang Y,Liu X,et al.Triptolide:pharmacological spectrum,biosynthesis,chemical synthesis and derivatives[J].Theranostics,2021,11(15):7199-7221.
[8] Yu GM,Zhou LF,Zeng BX,et al.The antioxidant effect of triptolide contributes to the therapy in a collagen-induced arthritis rat model[J].Redox Rep,2021,26(1):197-202.
[9] 邓雍钲,孟庆良,马俊福,等.痛风汤对急性痛风性关节炎模型大鼠踝关节滑膜组织中NLRP3炎症小体及NETs的影响[J].中医杂志,2024,65(17):1816-1824.
[10] Lv C,Cheng T,Zhang B,et al.Triptolide protects against podocyte injury in diabetic nephropathy by activating the Nrf2/HO-1 pathway and inhibiting the NLRP3 inflammasome pathway[J].Ren Fail,2023,45(1):2165103. |
|
|
|
2025, Vol. 31 
